The HARMONY Alliance is using Big Data to develop more personalized treatments for blood cancer patients. This is a team effort involving hospitals, academic institutions, pharmaceutical companies, regulatory agencies, and patient organizations. In 2021, we organized the BigDataForBloodCancer awareness campaign in synchrony with the virtual annual congress of the European Hematology Association (EHA2021). We engaged with clinicians and researchers to explain what Big Data can mean for the daily work of doctors and researchers and for the lives of patients.
Scan, read or watch our selected content below and find out how innovative big data analytic tools can speed up research for the good of the patients.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
